KLRC1 and neoplasm: ICIs work by blocking inhibitory receptors such as PD-1, CTLA-4, NKG2A, and TIGIT, which are used by tumors to evade immune surveillance, thereby promoting more effective and durable anti-tumor responses [4,5].